TNM classification of TCC in patients with NY-ESO-1 antibody
| Patient | Primary tumor | Metastasis | |
|---|---|---|---|
| Regional lymph node | Systemic | ||
| TCC 11 | CIS | − | − |
| TCC 18a | T1 + CIS | − | − |
| TCC 21 | T3b | − | − |
| TCC 22a | T4 | + | + |
| TCC 25 | CIS | − | − |
| TCC 38 | T2 | − | − |
| TCC 44b | CIS | − | − |
| TCC 84a | T1 + CIS | − | − |
| TCC 91 | T3b | − | − |
a Tumor specimens with NY-ESO-1 expression confirmed by immunohistostaining. Frozen specimens from TCC18 for RT-PCR were not available.
b Patient TCC44 has been tumor free since September 1995 after transurethral resection of bladder tumor followed by BCG immunotherapy. Serum for NY-ESO-1 antibody test was obtained in October 1997. Sera from the 8 other patients were obtained at the time of surgical resection of their tumors.